78574-94-4
Chemical Structure
Cycloastragenol
Synonym(s): Astramembrangenin; Cyclosieversigenin
- CAS No.: 78574-94-4
- Formula:C30H50O5
- Molecular Weight:490.72
IUPAC Name: (2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyltetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthrene-4,7,9-triol
InChIKey: WENNXORDXYGDTP-UOUCMYEWSA-N
SMILES: CC1(C)[C@@H](O)CC[C@]2(C3)[C@]43CC[C@]5(C)[C@@H]([C@](C)(O6)CC[C@H]6C(C)(O)C)[C@@H](O)C[C@](C)5[C@]4([H])C[C@H](O)[C@@]12[H]
Biological Activity: Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cycloastragenol | 99.95% | Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cycloastragenol (Standard) | 99.96% | Cycloastragenol (Standard) is the analytical standard of Cycloastragenol. This product is intended for research and analytical applications. Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yu Y, et al. Cycloastragenol: An exciting novel candidate for age-associated diseases. Exp Ther Med. 2018;16(3):2175-2182. [Content Brief]
- [2]. Li M, et al. Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia. Acta Pharmacol Sin. 2020;41(8):1025-1032. [Content Brief]
- [3]. Yu Y, et al. Cycloastragenol prevents age-related bone loss: Evidence in d-galactose-treated and aged rats. Biomed Pharmacother. 2020;128:110304. [Content Brief]
